The Global Hepatitis C Drugs Market Continues To Grow Owing To the High Incidence of Hepatitis C in the World

 

Hepatitis C Drugs

Hepatitis C Drugs Market, by Drug Type (Interferon Based Therapies, NS5A Inhibitors, NS5B Inhibitors, and Protease Inhibitors), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027.

Market Overview:

The Hepatitis C virus causes an infection of the liver, which can be a serious illness. Hepatitis C can lead to liver failure and even cancer if it is not treated. Fortunately, there are several treatment options to cure this disease and lower the risk of these complications. Acute hepatitis C can be treated by taking antiviral medicines. These medications can clear hepatitis C, usually within 6 months. Chronic hepatitis C is more serious and can lead to severe liver damage and even death. Most people who get chronic hepatitis C will need to take medications for the rest of their lives unless they have liver transplants. Tests to detect hepatitis C include HCV RNA and liver function tests. These tests measure the number of viral RNA (genetic material from the hepatitis C virus) particles and enzyme levels in the liver.

Competitive Landscape:

Major players operating in the global Hepatitis C Drugs Market include Kadmon Holdings, Inc., Natco Pharma Limited, Johnson & Johnson, Merck & co., Inc., F Hoffmann-la Roche Ltd, BRISTOL-MYERS Squibb Company., Gilead sciences, Inc., and Abbvie Inc.

Key Market Drivers:

The increasing incidence of hepatitis C infections in the world is expected to augment the growth of the global Hepatitis C Drugs Market. For instance, according to the World Health Organization, globally around 58 million individuals suffer from chronic hepatitis C virus infection, and around 1.5 million new cases occur every year. The hepatitis C virus can live in the liver for years before showing any symptoms, so these tests are important to detect the infection. The doctor will do blood tests to check for hepatitis C. Having these tests will also help identify which types of medications patients need to take for treatment. Moreover, the high prevalence of pharmaceutical and biotech sectors in the world is estimated to enhance the growth of the global hepatitis C drugs market.

Covid-19 Impact Analysis:

During the COVID-19 pandemic, the global Hepatitis C Drugs Market witnessed several challenges. The increasing burden on the healthcare sector restrained the growth of the market. Moreover, several pharmacological and biotechnological processes were postponed, which impacted market growth.

Key Takeaways:

·       North America is expected to dominate the growth of the global Hepatitis C Drugs Market, owing to the high incidence of hepatitis C cases in the region. For instance, according to the United States National Institute of Diabetes and Digestive and Kidney Diseases, around 3.9 million individuals in the United States suffer from chronic hepatitis C infections.

·       The Asia Pacific is estimated to witness high growth in the global hepatitis C drugs market, owing to the increasing approval of hepatitis C drugs in the region. For instance, according to The Times of India, Natco Pharma introduced a fixed dose combination of Sofosbuvir-Daclatasvir tablets, in order to treat hepatitis C infections.

Comments

Popular posts from this blog

Forging has significant application in creation of various metal for wide range of applications

Ginseng Market Outlook, Analysis and forecast up to 2028

The Vaccine Contract Manufacturing Industry to Flourish Due to Urgent Need to Develop Reliable and Cost-Effective Vaccines against Covid-19